<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804373</url>
  </required_header>
  <id_info>
    <org_study_id>13 6872 03</org_study_id>
    <nct_id>NCT02804373</nct_id>
  </id_info>
  <brief_title>Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome</brief_title>
  <acronym>PRADOTIM</acronym>
  <official_title>Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator thinks that the oxytocin (OT) can improve durably and significantly the
      behavior disorders and thus the socialization but also the satisfaction and could thus be an
      interesting therapeutic alternative for the patients presenting a Prader-Willi Syndrome
      (SPW). Although today several studies demonstrated the effects of the OT in various domains
      of the behavior, the investigator do not know either its specificity of action about the
      cerebral level, or its duration of action, or the optimal modalities of administration and in
      particular at patients SPW.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Behaviour as assessed by score variations in specific questionaries</measure>
    <time_frame>Every day before and after administration of treatment during 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in eating Behaviour as assessed by score variations in specific questionaries</measure>
    <time_frame>Every day before and after administration of treatment during 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in eating behaviour as assessed by score variations in hunger visual analogic scale</measure>
    <time_frame>Every day before and after administration of treatment during 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Metabolism variations as assessed by Positron Emission Tomography (PET-scan)</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
    <description>Brain imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Metabolism variations as assessed by functional Magnetic Resonance Imaging (f-RMI)</measure>
    <time_frame>Day 1, day 2 and day 29</time_frame>
    <description>Brain imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of social skills assessed by specific questionnaires</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of executive function assessed by specific questionnaires</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of theory of mind assessed by specific questionnaires</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social processing assessed by oculomotor exploration</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multisensory processing assessed by Neurovisual task</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormon blood concentration levels as assessed by bioassays</measure>
    <time_frame>Day 2 and day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>placebo daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily administration of placebo during 28 days : placebo continuous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 IU of oxytocin daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 IU of daily oxytocin administration during 28 days : oxytocin continuous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 IU of oxytocin every 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 IU of daily oxytocin every 3 days and placebo the following 2 days after each oxytocin administration during 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin continuous</intervention_name>
    <description>Administration of 24 IU of oxytocin daily during 28 days</description>
    <arm_group_label>24 IU of oxytocin daily</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily during 28 days</description>
    <arm_group_label>24 IU of oxytocin every 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo continuous</intervention_name>
    <description>Placebo administration the following 2 days after each OXT administration, during 28 days.</description>
    <arm_group_label>placebo daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Administration of 24 IU of oxytocin every 3 days during 28 days.</description>
    <arm_group_label>24 IU of oxytocin every 3 days</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prader-Willi syndrome genetically confirmed

          -  Absence of extension of the QT interval in the electrocardiogram

          -  Absence of hypokalemia

        Exclusion Criteria:

          -  Psychiatric troubles

          -  Anomalies of the heart rhythm in significant ECG

          -  Hepatic insufficiency

          -  Renal insufficiency

          -  Patients presenting a pregnancy or breast-feeding

          -  High sensibility to OT

          -  High sensibility to the excipients of the product

          -  Patients having family history of genetic pathology causing an extension of the
             interval QT

          -  Patients having risk factors of advanced twist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maithé TAUBER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maïthé TAUBER</last_name>
    <email>tauber.m@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de référence Prader-Willi - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maïthé Tauber</last_name>
      <email>tauber.m@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marion Valette</last_name>
      <email>valette.m@chu-toulouse.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

